Can-Fite BioPharma Ltd. (TLV:CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA 444.70
-8.70 (-1.92%)
Apr 28, 2026, 5:01 PM IDT
Can-Fite BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 0.41 | 0.67 | 0.74 | 0.81 | 0.85 | Upgrade
|
| Revenue Growth (YoY) | -39.91% | -9.29% | -8.27% | -5.04% | 11.80% | Upgrade
|
| Gross Profit | 0.41 | 0.67 | 0.74 | 0.81 | 0.85 | Upgrade
|
| Selling, General & Admin | 3.66 | 3.05 | 2.96 | 3.14 | 3.85 | Upgrade
|
| Research & Development | 6.69 | 5.76 | 5.98 | 7.76 | 9.85 | Upgrade
|
| Operating Expenses | 10.36 | 8.8 | 8.94 | 10.91 | 13.7 | Upgrade
|
| Operating Income | -9.95 | -8.13 | -8.2 | -10.1 | -12.84 | Upgrade
|
| Interest & Investment Income | 0.28 | 0.29 | 0.51 | 0.22 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.14 | -0.01 | 0.06 | -0.05 | 0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -9.82 | -7.87 | -7.65 | -9.94 | -12.78 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0 | -0.01 | 0.01 | -0.23 | 0.16 | Upgrade
|
| Pretax Income | -9.83 | -7.88 | -7.63 | -10.17 | -12.62 | Upgrade
|
| Earnings From Continuing Operations | -9.83 | -7.88 | -7.63 | -10.17 | -12.62 | Upgrade
|
| Net Income | -9.83 | -7.88 | -7.63 | -10.17 | -12.62 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 2.59 | Upgrade
|
| Net Income to Common | -9.83 | -7.88 | -7.63 | -10.17 | -15.21 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 126.97% | 70.22% | 56.71% | 47.49% | 54.32% | Upgrade
|
| EPS (Basic) | -5.97 | -10.86 | -17.92 | -37.41 | -82.48 | Upgrade
|
| EPS (Diluted) | -5.97 | -10.86 | -17.92 | -37.41 | -82.48 | Upgrade
|
| Free Cash Flow | -8.95 | -7.64 | -8.44 | -10.81 | -9.87 | Upgrade
|
| Free Cash Flow Per Share | -5.44 | -10.54 | -19.81 | -39.76 | -53.53 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -2456.79% | -1206.23% | -1102.96% | -1246.42% | -1505.51% | Upgrade
|
| Profit Margin | -2426.67% | -1169.14% | -1027.46% | -1255.93% | -1782.53% | Upgrade
|
| Free Cash Flow Margin | -2210.12% | -1133.83% | -1136.20% | -1334.57% | -1156.98% | Upgrade
|
| EBITDA | -9.93 | -8.12 | -8.18 | -10.08 | -12.83 | Upgrade
|
| D&A For EBITDA | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | Upgrade
|
| EBIT | -9.95 | -8.13 | -8.2 | -10.1 | -12.84 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.